Online citations, reference lists, and bibliographies.

Guideline: Vulvovaginal Candidosis (AWMF 015/072), S2k (excluding Chronic Mucocutaneous Candidosis).

W. Mendling, J. Brasch, O. Cornely, I. Effendy, Klaus Friese, G. Ginter‐Hanselmayer, H. Hof, P. Mayser, I. Mylonas, M. Ruhnke, M. Schaller, E-R Weissenbacher
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The oestrogenised vagina is colonised by Candida species in at least 20% of women; in late pregnancy and in immunosuppressed patients, this increases to at least 30%. In most cases, Candida albicans is involved. Host factors, particularly local defence mechanisms, gene polymorphisms, allergies, serum glucose levels, antibiotics, psycho-social stress and oestrogens influence the risk of candidal vulvovaginitis. Non-albicans species, particularly Candida glabrata, and in rare cases also Saccharomyces cerevisiae, cause less than 10% of all cases of vulvovaginitis with some regional variation; these are generally associated with milder signs and symptoms than normally seen with a C. albicans-associated vaginitis. Typical symptoms include premenstrual itching, burning, redness and odourless discharge. Although itching and redness of the introitus and vagina are typical symptoms, only 35-40% of women reporting genital itching in fact suffer from vulvovaginal candidosis. Medical history, clinical examination and microscopic examination of vaginal content using 400× optical magnification, or preferably phase contrast microscopy, are essential for diagnosis. In clinically and microscopically unclear cases and in chronically recurring cases, a fungal culture for pathogen determination should be performed. In the event of non-C. albicans species, the minimum inhibitory concentration (MIC) should also be determined. Chronic mucocutaneous candidosis, a rarer disorder which can occur in both sexes, has other causes and requires different diagnostic and treatment measures. Treatment with all antimycotic agents on the market (polyenes such as nystatin; imidazoles such as clotrimazole; and many others including ciclopirox olamine) is easy to administer in acute cases and is successful in more than 80% of cases. All vaginal preparations of polyenes, imidazoles and ciclopirox olamine and oral triazoles (fluconazole, itraconazole) are equally effective (Table ); however, oral triazoles should not be administered during pregnancy according to the manufacturers. C. glabrata is not sufficiently sensitive to the usual dosages of antimycotic agents approved for gynaecological use. In other countries, vaginal suppositories of boric acid (600 mg, 1-2 times daily for 14 days) or flucytosine are recommended. Boric acid treatment is not allowed in Germany and flucytosine is not available. Eight hundred-milligram oral fluconazole per day for 2-3 weeks is therefore recommended in Germany. Due to the clinical persistence of C. glabrata despite treatment with high-dose fluconazole, oral posaconazole and, more recently, echinocandins such as micafungin are under discussion; echinocandins are very expensive, are not approved for this indication and are not supported by clinical evidence of their efficacy. In cases of vulvovaginal candidosis, resistance to C. albicans does not play a significant role in the use of polyenes or azoles. Candida krusei is resistant to the triazoles, fluconazole and itraconazole. For this reason, local imidazole, ciclopirox olamine or nystatin should be used. There are no studies to support this recommendation, however. Side effects, toxicity, embryotoxicity and allergies are not clinically significant. Vaginal treatment with clotrimazole in the first trimester of a pregnancy reduces the rate of premature births. Although it is not necessary to treat a vaginal colonisation of Candida in healthy women, vaginal administration of antimycotics is often recommended in the third trimester of pregnancy in Germany to reduce the rate of oral thrush and napkin dermatitis in healthy full-term newborns. Chronic recurrent vulvovaginal candidosis continues to be treated in intervals using suppressive therapy as long as immunological treatments are not available. The relapse rate associated with weekly or monthly oral fluconazole treatment over 6 months is approximately 50% after the conclusion of suppressive therapy according to current studies. Good results have been achieved with a fluconazole regimen using an initial 200 mg fluconazole per day on 3 days in the first week and a dosage-reduced maintenance therapy with 200 mg once a month for 1 year when the patient is free of symptoms and fungal infection (Table ). Future studies should include Candida autovaccination, antibodies to Candida virulence factors and other immunological experiments. Probiotics with appropriate lactobacillus strains should also be examined in future studies on the basis of encouraging initial results. Because of the high rate of false indications, OTC treatment (self-treatment by the patient) should be discouraged.
This paper references
10.1055/S-0031-1280203
Die Vakzination mit inaktivierten Laktobazillen oder mit Heliotherapie kann die Lebensqualität von Frauen mit chronisch rezidivierender vulvovaginaler Kandidose verbessern – Eine prospektive 3-armige randomisierte Studie
W. Mendling (2011)
10.1055/S-0031-1299954
Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections.
V. Della Casa (2002)
10.1093/clinids/16.1.93
Vaginitis due to Saccharomyces cerevisiae: epidemiology, clinical aspects, and therapy.
J. Sobel (1993)
10.1016/J.AJOG.2005.03.034
Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories.
A. J. Phillips (2005)
Prevalence of Candida glabrata
D Ray (2000)
ventional antimycotic therapy
D Molgaard-Nielsen (2006)
10.1111/j.1471-0528.2002.01142.x
Oral versus intra‐vaginal imidazole and triazole anti‐fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review
M. Watson (2002)
10.1111/J.1439-0507.1998.TB00594.X
Vulvovaginitis due to Candida glabrata. An emerging problem.
J. Sobel (1998)
10.1016/J.AJOG.2005.03.068
Signs of chronic stress in women with recurrent candida vulvovaginitis.
Sophia Ehrström (2005)
10.1016/S0084-3954(07)70231-2
Prospective Randomised Controlled Trial of an Infection Screening Programme to Reduce the Rate of Preterm Delivery
J. Stockman (2006)
10.1089/154099903322643901
Candida transmission and sexual behaviors as risks for a repeat episode of Candida vulvovaginitis.
B. Reed (2003)
10.1186/1471-2334-2-1
Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes
Ella M de Leon (2002)
10.1007/BF00436669
Utilization of siderophores by Candida albicans
A. Ismail (1986)
10.1002/14651858.CD002845.PUB2
Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush).
M. Nurbhai (2007)
10.1111/J.1439-0507.2005.01164.X
The serum levels of calcium, magnesium, iron and zinc in patients with recurrent vulvovaginal candidosis during attack, remission and in healthy controls.
J. Špaček (2005)
10.1016/S1369-5274(00)00230-7
Protist tubulins: new arrivals, evolutionary relationships and insights to cytoskeletal function.
K. Gull (2001)
10.1093/infdis/161.6.1276
Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis.
F. de Bernardis (1990)
Multilocus sequence typing of Candida africana from patients with vulvovaginal candidiasis
C Sharma (2014)
Self-reported yeast symptoms compared with clinical wet mount analysis and vaginal yeast culture in a specialty clinic setting.
S. Hoffstetter (2008)
Vaginal Colonisation with Candida Species with Special Focus on Candida dubliniensis. A Prospective Study
W Mendling (2007)
Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/OAG) (AWMF 055/066)
Austrian Aids (2013)
Die Torulopsidose 1 in der Frauenheilkunde 2
W. Mendling (1984)
10.1053/JINF.2000.0723
Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status.
R. Goswami (2000)
10.1016/S0029-7844(98)00264-6
Vulvovaginal Candidiasis: Clinical Manifestations, Risk Factors, Management Algorithm
L. Eckert (1998)
10.5694/J.1326-5377.2003.TB05418.X
"Not thrush again!" Women's experience of post-antibiotic vulvovaginitis.
M. Pirotta (2003)
Not thrush again
MV Pirotta (2009)
10.1128/JCM.02485-07
Survey of Vaginal-Flora Candida Species Isolates from Women of Different Age Groups by Use of Species-Specific PCR Detection
John-Paul Vermitsky (2008)
Identification of a 173 – estradiol – binding protein in Candida albicans and Candida ( Torulopsis ) glabrata
BL Powell (1980)
10.1111/j.1365-2133.1950.tb10963.x
An Epidemiological Survey
G. Whitwell (1950)
10.1111/J.1439-0507.2006.01235.X
Stress as a cause of chronic recurrent vulvovaginal candidosis and the effectiveness of the conventional antimycotic therapy.
Harald Meyer (2006)
10.1097/01.AOG.0000164808.23937.8E
Vaginal yeast colonization in nonpregnant women: a longitudinal study.
G. Dennerstein (2005)
An outline of the role
A Cassone (1987)
10.1111/J.1439-0507.1981.TB01827.X
Doppelblind‐Vergleichsstudie mit Ciclopiroxolamin‐ und Miconazol‐Vaginalcreme bei uilvovaginaler Candidose
M. Wajnberg (2009)
10.17169/REFUBIUM-9312
Die Hormonspirale als Risikofaktor für chronische Infektionen
W. V. Zglinicki (2011)
10.1016/j.ajog.2008.06.029
Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial).
G. Donders (2008)
10.1055/S-0034-1368243
Three-Day Combination Treatment for Vulvovaginal Candidosis with 200 mg Clotrimazol Vaginal Suppositories and Clotrimazol Cream for the Vulva is Significantly Better than Treatment with Vaginal Suppositories Alone - an Earlier, Multi-Centre, Placebo-Controlled Double Blind Study.
W. Mendling (2014)
10.1007/s00404-008-0681-9
Relationship between clinical diagnosis of recurrent vulvovaginal candidiasis and detection of Candida species by culture and polymerase chain reaction
T. Weissenbacher (2008)
Use of fluconazole during pregnancy and risk of birth defects
D Molgaard-Nielsen (2013)
10.1016/j.diagmicrobio.2009.03.021
Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy.
Zainab Shahid (2009)
10.1086/517314
Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype.
W. Chaim (1997)
Ultrastruktur von Candida albicans unter Einwirkung von PolyenAntibiotika
anderungen der (1980)
10.20396/BJOS.V5I16.8641872
Candida albicans proteinases
R. C. Mardegan (2006)
Itraconazole vs fluconazole
E Pitsoni (2006)
10.1016/0091-6749(88)90909-8
A localized vaginal allergic response in women with recurrent vaginitis.
S. Witkin (1988)
Ver € anderungen der Ultrastruktur von Candida albicans unter Einwirkung von PolyenAntibiotika
ND Scheklakow (1980)
10.1111/J.1439-0507.1968.TB03398.X
Epidemiologische Untersuchungen zum Vorkommen von Hefepilzen bei Kindern und deren Müttern
R. Blaschke-Hellmessen (2009)
10.1111/j.1471-0528.1986.tb07818.x
Co‐treatment of the male partner in vaginal candidosis: a double‐blind randomized control study
M. P. Bisschop (1986)
10.1111/J.1439-0507.2006.01284.X
A 5-year (2000-2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria.
A. Paulitsch (2006)
10.1111/j.1479-828X.2001.tb01238.x
Oestrogen, glycogen and vaginal candidiasis
G. Dennerstein (2001)
10.3122/jabfm.2008.04.070169
Effect of Antibiotics on Vulvovaginal Candidiasis: A MetroNet Study
J. Xu (2008)
10.1111/myc.1990.33.6.265
Pathogenicity determinants of Candida.
M. Ghannoum (1990)
Vulvovaginitis due to Candida glabrata
JD Sobel (1998)
Antimykotische Therapie der vaginalen HefepilzKolonisation von Schwangeren zur Verh € utung von Kandidamykosen beim Neugeborenen
W Mendling (2008)
10.1038/nri1255
Immunity to fungal infections
L. Romani (2004)
10.1111/j.1439-0507.1983.tb03224.x
Terminologie der Humanmykosen/ Terminology of Human Mycoses
W Löffler (2009)
10.1016/S0002-9378(85)80011-9
Is more than one application of an antifungal necessary in the treatment of acute vaginal candidiasis?
L. Cohen (1985)
10.1097/00006250-198003000-00029
Microbial flora associated with Candida albicans vulvovaginitis.
P. Auger (1980)
10.3950/jibiinkoka.64.157
DISTRIBUTION OF CANDIDA IN THE MOUTH
Yasuyo Takeshita (1961)
10.1159/000238156
Epidemiology and the prevention of peripartal mycoses.
J. Schnell (1982)
10.1086/322600
Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals.
B. Mathema (2001)
Signs of chronic
SM Ehrstr€om (1998)
10.1111/J.1439-0507.1998.TB00598.X
[Vertical transmission of Candida and its consequences].
R. Blaschke-Hellmessen (1998)
10.1126/scitranslmed.3002613
Repeated Vulvovaginal Fungal Infections Cause Persistent Pain in a Mouse Model of Vulvodynia
Melissa A. Farmer (2011)
10.1089/15246090050020745
Single-dose miconazole nitrate vaginal ovule in the treatment of vulvovaginal candidiasis: two single-blind, controlled studies versus miconazole nitrate 100 mg cream for 7 days.
D. Upmalis (2000)
10.1111/J.1439-0507.2006.01192.X
The glyoxylate cycle enzyme activities in the pathogenic isolates of Candida albicans obtained from HIV/AIDS, diabetic and burn patients.
A. A. Lattif (2006)
10.1016/J.BPOBGYN.2007.02.002
Asymptomatic trichomonas and candida colonization and pregnancy outcome.
P. Hay (2007)
C-type lectin Langerhans is a beta-glucan receptor on human Langerhans cells that recognize opportunistic and pathogenic
MA De Jong (2010)
10.1111/J.1439-0507.1998.TB00598.X
Subpartale Übertragung von Candida und ihre Konsequenzen
R. Blaschke-Hellmessen (1998)
10.2337/diacare.21.3.451
Treatment of Vulvovaginal Candidiasis in Patients With Diabetes
N. Bohannon (1998)
10.1080/00365540601148491
Distribution of Candida species in women with vulvovaginal symptoms and their association with different ages and contraceptive methods
Meryem Çetin (2007)
10.1016/J.AJOG.2007.10.786
Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials.
E. Pitsouni (2008)
10.1128/AAC.47.1.34-38.2003
Fluconazole Susceptibility of Vaginal Isolates Obtained from Women with Complicated Candida Vaginitis: Clinical Implications
J. Sobel (2003)
10.1111/j.1439-0507.2010.01967.x
Potential role of probiotic bacteria in the treatment and prevention of localised candidosis.
D. Mailänder-Sánchez (2012)
10.1111/j.1471-0528.2009.02262.x
Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial
A. Witt (2009)
10.1016/j.ijgo.2006.11.003
Candida autovaccination in the treatment of vulvovaginal Candida infections
K. Rusch (2007)
10.2174/1566524054022549
An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis.
A. Cassone (2005)
10.1007/S00105-012-2377-0
[Candida glabrata : pathogenicity and therapy update].
Tietz Hj (2012)
10.3109/00016348209156578
Treatment of Vaginal Candidosis with Natamycin and Effect of Treating the partner at the same time
A. Buch (1982)
10.1016/0002-9378(90)90380-P
Recurrent allergic vulvovaginitis: treatment with Candida albicans allergen immunotherapy.
D. Rigg (1990)
10.1002/14651858.CD000225
Topical treatment for vaginal candidiasis (thrush) in pregnancy.
G. Young (2001)
10.1136/sti.2003.004192
Vulvovaginal candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse
E. Rylander (2004)
10.1016/j.ejogrb.2009.01.010
Relationship between recurrent vulvovaginal candidosis and immune mediators in vaginal fluid.
T. Weissenbacher (2009)
10.1007/0-387-25445-5_17
The Role of Humoral Immunity against Vaginal Candida Infection
F. Bernardis (2005)
10.1016/0147-5975(84)90054-9
Identification of a17β-estradiol binding protein inCandida albicans andCandida (Torulopsis) glabrata
Bernard L. Powell (1984)
10.1016/S0301-2115(03)00096-4
An epidemiological survey of vulvovaginal candidiasis in Italy.
S. Corsello (2003)
Recurrent vulvovaginitis candidiasis; an overview of traditional and alternative therapies.
Candy Wilson (2005)
Vaginal candida parapsilosis
P Nyirjesy (1995)
Effect of Lactobacillus rhamsosus GR-1 and Lactobacillus reuteri RC-14 on the ability of Candida albicans to infect cells and include inflammation
RC Martinez (2009)
10.3109/13693780902856626
Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis.
M. E. Auler (2010)
Cotreatment of the male partner in vaginal candidosis: a double-blind randomised controlled-study
Bisshop MPJM (1986)
10.1016/S0010-7824(02)00537-1
A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
U. Gaspard (2003)
10.14670/HH-29.10.567
Infection through structured polymicrobial Gardnerella biofilms (StPM-GB).
A. Swidsinski (2014)
10.1136/bmj.38210.494977.DE
Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial
M. Pirotta (2004)
10.1155/2005/401530
Vaginal Candida parapsilosis: pathogen or bystander?
P. Nyirjesy (2005)
10.1080/02681219280000021
Nomenclature of fungal diseases: a report and recommendations from a Sub-Committee of the International Society for Human and Animal Mycology (ISHAM).
F. Odds (1992)
10.1177/0884217503253439
Prevention and treatment of vulvovaginal candidiasis using exogenous Lactobacillus.
Heather S Jeavons (2003)
Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis.
J. Sobel (1985)
10.1159/000314022
Management of Recurrent Vulvo-Vaginal Candidosis as a Chronic Illness
G. Donders (2010)
10.1159/000321047
Antimicrobial Topical Agents Used in the Vagina
B. F. Tirri (2011)
10.1016/j.molimm.2009.12.016
C-type lectin Langerin is a β-glucan receptor on human Langerhans cells that recognizes opportunistic and pathogenic fungi
M. A. D. de Jong (2010)
10.1016/S0029-7844(01)01759-8
Over‐the‐Counter Antifungal Drug Misuse Associated With Patient‐Diagnosed Vulvovaginal Candidiasis
D. Ferris (2002)
10.21101/CEJPH.A3440
The use of data set of the Hungarian case-control surveillance of congenital abnormalities for evaluation of birth outcomes beyond birth defects.
A. Czeizel (2007)
Treatment of vaginal candidosis with fluconazole.
R. Herzog (1989)
10.3389/fmicb.2012.00294
New Approaches in the Development of a Vaccine for Mucosal Candidiasis: Progress and Challenges
A. Vecchiarelli (2012)
10.1186/1471-2393-11-18
Treatment of asymptomatic vaginal candidiasis in pregnancy to prevent preterm birth: an open-label pilot randomized controlled trial
C. Roberts (2011)
10.1128/JCM.00218-06
Genital Candida Species Detected in Samples from Women in Melbourne, Australia, before and after Treatment with Antibiotics
M. Pirotta (2006)
10.1007/978-3-662-10739-3
Vaginose, Vaginitis und Zervizitis
W. Mendling (1995)
10.1016/j.ajog.2015.06.067
Recurrent vulvovaginal candidiasis.
J. Sobel (2016)
10.1111/j.1439-0507.1996.tb00508.x
Voraussetzungen für eine effektive Therapie chronisch rezidivierender Vaginalcandidosen
V. Kunzelmann (1996)
10.1097/01.qco.0000160897.74492.a3
Immunity in vaginal candidiasis
P. Fidel (2005)
10.1093/infdis/143.1.76
Adherence of Candida albicans to human vaginal and buccal epithelial cells.
J. Sobel (1981)
10.1016/0029-7844(95)00047-U
Torulopsis glabrata Vaginitis
A. Spinillo (1995)
10.1136/sti.66.5.357
Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenstrual application of a 500 mg clotrimazole vaginal tablet.
A. Roth (1990)
Evidence for a role for secretory aspartate proteinase of Candida albicans in vulvovaginal candidosis
F de Bernardis (1990)
10.1128/CMR.13.1.122-143.2000
Potential role of phospholipases in virulence and fungal pathogenesis.
M. Ghannoum (2000)
Can intrauterine contra
F Chassot (1997)
10.1111/J.1439-0507.1998.TB00596.X
VERGLEICH DER STAMMSPEZIFITAT VON HEFEPILZEN VERSCHIEDENER LOKALISATION BEI FRAUEN MIT VAGINALCANDIDOSEN
W. Mendling (1998)
10.1111/j.1348-0421.2009.00154.x
Effect of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the ability of Candida albicans to infect cells and induce inflammation.
R. Martinez (2009)
10.1016/0140-6736(92)93174-L
Nomenclature of fungal diseases
F. Odds (1992)
10.1086/592249
Biased genotype distributions of Candida albicans strains associated with vulvovaginal candidosis and candidal balanoposthitis in China.
J. Li (2008)
10.1128/AAC.47.6.1805-1817.2003
Ciclopirox Olamine Treatment Affects the Expression Pattern of Candida albicans Genes Encoding Virulence Factors, Iron Metabolism Proteins, and Drug Resistance Factors
M. Niewerth (2003)
10.1016/J.JSS.2005.05.019
Candida albicans: the estrogen target for vaginal colonization.
W. Tarry (2005)
Candida glabrata : pathogenit € at und Stand der Dinge
HJ Tietz (2012)
10.1136/sti.68.6.374
The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis.
I. Fong (1992)
10.1093/JAC/DKL246
Probiotics for prevention of recurrent vulvovaginal candidiasis: a review.
M. Falagas (2006)
10.1111/j.1439-0507.2010.01939.x
Candida africana and its closest relatives.
O. Romeo (2011)
10.1097/OGX.0b013e31822bdf31
Diagnosis of Vaginal Discharge by Wet Mount Microscopy: A Simple and Underrated Method
I. Mylonas (2011)
Hyposensitisation in the management of recurring vaginal candidiasis.
N. Rosedale (1979)
10.1111/j.1471-0528.1985.tb04873.x
The pill does not cause ‘thrush’
F. Davidson (1985)
Prevalence and risk factors for vaginal Candida colonization in women with type I and type 2 diabetes
E de Leon (2002)
New insights into the immune pathogenesis of recurrent vulvovaginal candidiasis
SS Witkin (2000)
10.1056/NEJMe0907186
Yeast infections--human genetics on the rise.
S. Holland (2009)
10.1111/j.1365-2249.2005.02891.x
Association between atopy and recurrent vaginal candidiasis
N. Neves (2005)
10.1016/0020-7292(92)90676-A
Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis
E. Hilton (1992)
10.1111/J.1439-0507.1981.TB01851.X
Veränderungen der Ultrastruktur von Candida albicans unter der Einwirkung von Polyenantibiotika: Ultrastructural Changes in Candida Albicans caused by Polyene Antibiotics
N. D. Scheklakow (2009)
10.1111/J.1439-0507.1974.TB04509.X
Die Salzsaure-Toleranz von Candida albicans
W. Meinhof (2009)
10.1080/00362178385380391
Scanning electron microscope study of Candida albicans invasion of cultured human cervical epithelial cells.
S. Farrell (1983)
10.1093/infdis/156.5.777
Evidence for a correlation between proteinase secretion and vulvovaginal candidosis.
A. Cassone (1987)
10.1111/j.1471-0528.2008.01830.x
Mannose‐binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis
G. Donders (2008)
10.1097/00001648-199907000-00016
No teratogenic effect after clotrimazole therapy during pregnancy.
A. Czeizel (1999)
10.1055/s-2008-1036308
[Torulopsis in gynecology].
W. Mendling (1984)
Azoles in the therapy of vaginal candidosis
W. Mendling (1988)
10.1155/S1064744996000439
Investigations by Cell-Mediated Immunologic Tests and Therapeutic Trials With Thymopentin in Vaginal Mycoses
W. Mendling (1996)
10.1016/J.JINF.2005.03.005
Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy.
Deepti Goswami (2006)
10.1086/429246
Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis.
O. Babula (2005)
10.1111/myc.12193
Multilocus sequence typing of Candida africana from patients with vulvovaginal candidiasis in New Delhi, India.
C. Sharma (2014)
Candida albicans allergen immunotherapy in recurrent vaginal candidiasis.
P. Moraes (2000)
10.1001/JAMA.291.11.1368
Evaluation of vaginal complaints.
M. Anderson (2004)
Systemic and mucosal
M Raska (2007)
[Evaluation of the efficacity and speed of action of sertaconazole nitrate suppository and cream combined treatment for vulvovaginal candidiasis].
C. Quéreux (2000)
10.1016/S0002-9378(96)70119-9
Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole.
P. Mastroiacovo (1996)
10.1086/422397
Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells.
W. Ip (2004)
Gezieltes Vorgehen gegen Problemkeime
HJ Tietz (2009)
10.1111/J.1439-0507.1980.TB02551.X
Pharmakokinetik der Imidazol‐Antimykotika*)
M. Plempel (2009)
Quantitative Untersuchungen € uber die D € oderleinFlora gesunder sowie mykosekranker Probandinnen unter lokaler IsoconazolNitratTherapie
B Nold (1981)
10.1007/978-3-642-83312-0
Vulvovaginal Candidosis
Dr. Werner Mendling (1988)
10.1007/BF00668025
Das Verhalten von Sproßpilzen am nicht verhornenden Plattenepithel
J. D. Schnell (1974)
10.1007/s00404-002-0368-6
Topical antiseptics as an alternative in the treatment of acute vulvovaginal candidosis
Klaus Friese (2003)
10.2105/AJPH.80.3.329
The epidemiology of vulvovaginal candidiasis: risk factors.
B. Foxman (1990)
10.1128/JCM.43.5.2155-2162.2005
Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases
S. Richter (2005)
10.1016/j.contraception.2008.01.007
Can intrauterine contraceptive devices be a Candida albicans reservoir?
F. Chassot (2008)
10.1055/S-2007-965681
Die vaginale Kolonisation durch Candidaarten unter besonderer Berücksichtigung von Candida dubliniensis
Werner Mendling (2007)
10.1016/J.EJOGRB.2004.02.011
Preterm birth reduction after clotrimazole treatment during pregnancy.
A. Czeizel (2004)
10.1016/S0002-9378(99)70248-6
Vaginal heat shock protein expression in symptom-free women with a history of recurrent vulvovaginitis.
P. Giraldo (1999)
10.1097/AOG.0b013e3181909f63
Accuracy of the Clinical Diagnosis of Vaginitis Compared With a DNA Probe Laboratory Standard
N. Lowe (2009)
10.1080/13693780500096898
Immunotherapeutic approaches to enhance protective immunity against Candida vaginitis.
K. Wozniak (2005)
Grampian Evidence Based Community Phar
CM Bond (1998)
10.1016/j.mib.2012.04.004
Recent progress in vaccines against fungal diseases.
A. Cassone (2012)
10.1128/CMR.12.1.80
Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison toC. albicans
P. Fidel (1999)
10.1056/NEJMoa1301066
Use of oral fluconazole during pregnancy and the risk of birth defects.
D. Mølgaard-Nielsen (2013)
10.1067/MOB.2002.126285
Impaired tolerance for glucose in women with recurrent vaginal candidiasis.
G. Donders (2002)
10.1097/LGT.0b013e318273e8cf
Prevalence of Recurrent Vulvovaginal Candidiasis in 5 European Countries and the United States: Results From an Internet Panel Survey
B. Foxman (2013)
Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis
D Ray (2000)
10.1186/1477-7525-11-169
Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA
S. Aballéa (2013)
10.1007/s11046-008-9119-y
Two Cases of Vaginitis Caused by Itraconazole-Resistant Saccharomyces cerevisiae and a Review of Recently Published Studies
V. Savini (2008)
Identification of a 173 – estradiol – binding protein
BL Powell (1980)
10.1136/sti.2009.040386
Prevalence and management of non-albicans vaginal candidiasis
Nalin Hetticarachchi (2010)
10.1080/13693780701883508
Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis.
M. Raska (2008)
Pharmacokinetics of azole compounds
W. Ritter (1988)
10.1080/00362178285380341
A comparison of secretory proteinases from different strains of Candida albicans.
R. Rüchel (1982)
10.1111/J.1439-0507.2005.01127.X
Nine male cases of tinea genitalis.
C. Romano (2005)
10.1056/NEJMoa0901053
Human dectin-1 deficiency and mucocutaneous fungal infections.
B. Ferwerda (2009)
10.1023/A:1024842712675
The development of evidence‐ based guidelines for over‐ the‐ counter treatment of vulvovaginal candidiasis
C. Bond (2004)
10.1097/QAD.0b013e32836290b6
Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission
J. H. van de Wijgert (2013)
10.1111/J.1439-0507.2004.00970.X
A clinical multicenter study comparing efficacy and tolerability of topical combination therapy with clotrimazole (Canesten, two formats) with oral single dose fluconazole (Diflucan) in vulvovaginal mycoses.
W. Mendling (2004)
10.1086/343826
Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy.
S. Singh (2002)
10.1016/0002-9378(95)90347-X
Chronic fungal vaginitis: the value of cultures.
P. Nyirjesy (1995)
10.1056/NEJMOA033114
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.
J. Sobel (2004)
10.1136/STI.76.6.437
Vaginal yeasts in the era of “over the counter” antifungals
P. P. Walker (2000)
10.1111/j.1462-5822.2004.00439.x
Candida albicans proteinases and host/pathogen interactions
J. Naglik (2004)
10.1111/J.1439-0507.1998.TB00595.X
Kommentar zum vorstehenden Beitrag von J. D. Sobel
H. Tietz (1998)



This paper is referenced by
10.1016/J.RIAM.2016.11.006
Candidiasis vulvovaginal: una antigua enfermedad con nuevos desafíos
María Soledad Miró (2017)
10.1007/s10096-016-2715-8
Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504)
S Palacios (2016)
10.4172/2161-0932.1000475
Local Application of Propranolol and Treatment of Diabetic Vulovagnitis
Salwa Samir Anter (2018)
10.1016/j.ejps.2018.06.030
Lyophilized tablets for focal delivery of fluconazole and itraconazole through vaginal mucosa, rational design and in vitro evaluation
María José de Jesús Valle (2018)
10.1097/LGT.0000000000000532
Clinicopathologic Diagnostic Criteria for Vulvar Lichen Planus
Tania Day (2020)
10.1111/myc.12593
Comparison of two long‐term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study
Jiří Špaček (2017)
10.4236/OJOG.2015.59071
Alpha Defensins Genes and Vulvovaginal Candidiasis: A Study of Cases
Humberto Fabio Boatto (2015)
10.4103/jfmpc.jfmpc_584_19
The effect of curcumin-based and clotrimazole vaginal cream in the treatment of vulvovaginal candidiasis
Nilufar Abouali (2019)
10.1016/J.RIAM.2017.01.001
Vaginitis por Candida glabrata: ¿la gran olvidada?
Ana Arroyo-Fajardo (2017)
10.1016/j.xphs.2018.06.017
Amphotericin B-Loaded Poly(lactic-co-glycolic acid) Nanofibers: An Alternative Therapy Scheme for Local Treatment of Vulvovaginal Candidiasis.
Ramon Oliveira Souza (2018)
10.1007/978-81-322-2782-3_6
Recent Advancements in Combinational Antifungal Therapy and Immunotherapy
Sudarshan Singh Rathore (2016)
10.1111/lam.13034
Prevalence and antifungal susceptibility of Candida species among pregnant women attending a school maternity at Natal, Brazil.
Luiz Da Silta Brandao (2018)
10.2147/IDR.S247944
Current Aspects in the Biology, Pathogeny, and Treatment of Candida krusei, a Neglected Fungal Pathogen
Manuela Gómez-Gaviria (2020)
10.1016/j.annepidem.2017.08.010
Recurrent vulvovaginal candidiasis.
Freida A Blostein (2017)
10.1136/sextrans-2017-053343
Intravaginal boric acid: is it an alternative therapeutic option for vaginal trichomoniasis?
N. Thorley (2017)
10.1007/s00192-015-2884-5
Effect of norfloxacin therapy for acute, uncomplicated lower urinary tract infection on vaginal Candida prevalence
Rodrigo Cézar Magalhães Rocha (2015)
10.21518/2079-701x-2019-13-94-98
Sertaconazole in the treatment of vulvovaginal candidiasis
Z. N. Efendieva (2019)
10.21518/2079-701X-2018-13-96-102
Применение флуконазола у женщин репродуктивного возраста с вульвовагинальным кандидозом
Е. А. Межевитинова (2018)
10.7726/JCI.2016.1001
Effects of Probiotics against Candida Infections and Their Potential Use in Vulvovaginal Candidosis
Filippo Fassio (2016)
10.4236/OJOG.2017.71002
Polyhexamethylene Biguanide in Vaginal Solution Is Effective in the Treatment of Vulvovaginal Candidiasis: A Pilot Study
Alberto Biamonti (2017)
Topical Ciclopirox - Recalling a Forgotten Ally in the Fight against CutaneousMycoses
Sidharth Sonthalia (2018)
10.1007/978-981-10-6141-7_15
Roles of Candida albicans aspartic proteases in host-pathogen interactions
Mariusz Gogól (2017)
10.1111/omi.12206
Extracellular proteinases of Candida species pathogenic yeasts.
M. Rapala-Kozik (2018)
10.2478/afmnai-2018-0032
Comparison of the Effects of Artemisia Vaginal Cream and Clotrimazole on Vaginal Candidiasis Infection
Ala Saber Mohammad (2018)
10.1093/cid/civ746
Role of Echinocandins in Fungal Biofilm-Related Disease: Vascular Catheter-Related Infections, Immunomodulation, and Mucosal Surfaces.
A. Katragkou (2015)
10.1016/j.diabet.2015.07.002
Urinary and genital infections in patients with diabetes: How to diagnose and how to treat.
P. Njomnang Soh (2016)
10.1186/s12879-019-4736-2
Prevalence and antifungal susceptibility of Candida albicans causing vaginal discharge among pregnant women in Lebanon
Nahed Ghaddar (2020)
10.1177/0956462418785451
2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge
J. Sherrard (2018)
10.1186/s12866-018-1316-3
Nystatin enhances the immune response against Candida albicans and protects the ultrastructure of the vaginal epithelium in a rat model of vulvovaginal candidiasis
X. Zhang (2018)
10.1097/LGT.0000000000000366
Interpretation of Nondiagnostic Vulvar Biopsies
Tania Day (2018)
10.3390/antibiotics9020046
In vitro Antibiotic and Modulatory Activity of Mesosphaerum suaveolens (L.) Kuntze against Candida strains
Adrielle Rodrigues Costa (2020)
10.1007/978-3-319-61621-6_24
Candidiasis, Bacterial Vaginosis, Trichomoniasis and Other Vaginal Conditions Affecting the Vulva
Pedro Vieira-Baptista (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar